The Way You Breathe Could Reveal a Hidden Sign of Alzheimer's
Researchers from the UK and Slovenia have now found specific brain activity and breathing patterns can act as signs of Alzheimer's.
The team set out to study how oxygenation of the brain might be linked to neurodegenerative diseases, comparing measures of brain oxygenation, heart rate, brain waves, and breathing effort of 19 Alzheimer's patients to 20 people without Alzheimer's.
Their analysis found differences in neurons linked to blood vessels and in how blood oxygen levels fluctuated as neurons fired. The sync of blood flow and brain activity seems to be noticeably disrupted in Alzheimer's brains.
What's more, there was an unexpected extra: the Alzheimer's patients had a higher breathing rate than the control patients, around 17 breaths per minute compared to 13 breaths per minute. This is possibly a result of changes in how blood vessels in the brain connect with deeper nerve tissues to provide a generous supply of oxygen.
"This is an interesting discovery – in my opinion a revolutionary one – that may open a whole new world in the study of Alzheimer's disease," says biophysicist Aneta Stefanovska, from Lancaster University in the UK.
"It most likely reflects an inflammation, maybe in the brain, that once detected can probably be treated and severe states of Alzheimer's might be prevented in the future."
The setup for the analysis involves a variety of electrical and optical sensors on the scalp – but it doesn't require any blood or tissue samples, and is cheaper and quicker than a lot of other diagnosis options.
And while breathing patterns on their own wouldn't yet be enough to detect Alzheimer's, with so many other variables in play, researchers can now look at respiratory rates in future studies to build up a more complete picture of Alzheimer's symptoms.
This supports the hypothesis that Alzheimer's disease is triggered by a breakdown in the functioning of the brain's vascular system, which reduces the efficiency of oxygen flow and clearance of toxic materials.
"The vascular system and the brain work together to ensure that the brain receives sufficient energy," says neurologist Bernard Meglič, from the University of Ljubljana in Slovenia.
"In fact, the brain needs as much as 20 percent of the body's overall energy consumption despite contributing only about 2 percent of the body's weight."
There's much to consider with Alzheimer's – from symptoms to risk factors – that it's likely that a combination of causes are working in combination, but research like this helps get us closer to understanding the disease's progression.
"We show clear results of our approach and how Alzheimer's can be detected simply, noninvasively, and inexpensively," says Stefanovska.
"The method has great potential, and we are discussing possibilities to create a spin-out or start-up company to proceed with it. Of course, more research is needed."
The research has been published in Brain Communications.
Yogurt Shows Great Potential Against Colon Cancer, Study Reveals
This New Drug Mimics The Health Effects of Living at High Altitude
The Seeds of Schizophrenia May Be Planted in The Earliest Moments of Life
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
7 hours ago
- Hamilton Spectator
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on , building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080 BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab) LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide . About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at . Follow us on social media - Facebook , LinkedIn , X , YouTube . Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Business Wire
8 hours ago
- Business Wire
Ellis George LLP: CA Court of Appeal Upholds $5 Million Jury Verdict Against Bristol-Meyers-Squibb-owned Impact Biomedicines
SAN DIEGO--(BUSINESS WIRE)-- Ellis George LLP announced that The California Court of Appeal, Fourth Appellate District, has reversed a trial court order that reduced a jury verdict against Impact Biomedicines and instead reinstated the original $5,020,000 award. Impact Biomedicines, a division of Bristol-Meyers-Squibb, and Impact Biomedicine's founder and owner, Dr. John Hood, must pay San Diego physician and Alzheimer's researcher James Brewer M.D., Ph.D., more than $1 million in compensatory damages and $4 million in punitive damages in a fraudulent concealment case filed in 2019. Dr. Brewer, chair of the neurology department at UC San Diego, was represented by Christopher W. Arledge and Courtney L. Mitchell, both of Ellis George LLP, and Peter Afrasiabi of One LLP. At trial in the San Diego County Superior Court, a 12-member jury awarded Dr. Brewer more than $5 million, finding that Impact Biomedicines and Dr. Hood had defrauded Dr. Brewer as part of Impact Biomedicines' effort to end an FDA-mandated clinical hold and get Impact Biomedicines' experimental cancer drug approved. The jury accepted Dr. Brewer's argument that Impact Biomedicines and Dr. Hood had misled the FDA about the work Dr. Brewer had done for them and the conclusions he had reached and then concealed its false statements to the FDA from Dr. Brewer. Later, the trial court agreed that Dr. Brewer had proven his fraud case but reduced the damages number significantly. At the time, Mr. Arledge said he disagreed with the court's decision to reduce the damages and predicted that the trial court's order would be reversed on appeal. Today it was. According to the Court of Appeal's opinion, 'We conclude that substantial evidence supports the jury's findings on liability and damages, and the jury's award of punitive damages was not constitutionally excessive…' 'This was a hard-fought win against a very well-funded opponent and one of the largest, most-prestigious law firms in the country. Now a jury, a trial court, and an appellate court have all agreed that Dr. Brewer proved his fraud claim, and we're grateful to the Court of Appeal for recognizing that the trial court's reduction in Dr. Brewer's damages was a legal error,' said Mr. Arledge. 'This is an important win for Dr. Brewer and for patients who must be able to rely on the FDA drug-approval process.' Impact Biomedicines was represented by Colleen C. Smith, John T. Ryan, Andrew R. Gray, and Melissa Arbus Sherry, all of Latham & Watkins. James Brewer v Impact Biomedicines, et al. Superior Court No. 37-2019-00067876-CU-CO-CTL About Ellis George LLP Ellis George LLP is an elite litigation and trial firm based in Los Angeles and with offices in San Francisco and New York. Whether plaintiff or defendant, individual, Fortune 500 corporation or entrepreneur, clients call upon Ellis George when seeking litigation counsel of the highest quality, creativity, dedication, and ethics. Visit
Yahoo
10 hours ago
- Yahoo
Scientists Discovered a New Alzheimer's Warning Sign—and It Has to Do With Your Sleep
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Alzheimer's disease is a devastating condition that impacts millions of families around the world. But scientists are still trying to pinpoint the elements that go into why some people develop Alzheimer's disease and others don't. Now, a new study suggests that your sleep patterns may play a role. The study, which was published in the journal Alzheimer's & Dementia, specifically looked at the relationship between REM sleep and Alzheimer's disease. But what's the link between the two and, more importantly, how can you use this information to lower your risk of developing Alzheimer's disease? A neurologist explains. Meet the expert: W. Christopher Winter, MD, a neurologist and sleep medicine physician with Charlottesville Neurology and Sleep Medicine and host of the podcast. What did the study find? For the study, researchers looked at how long it took 123 people to reach rapid eye movement (REM) sleep for the first time after falling asleep, as well as several biomarkers linked to Alzheimer's disease. (REM sleep is a stage of sleep where your eyes move quickly and you dream, per the Cleveland Clinic. It's important for learning and memory, too.) Of the participants, 64 had Alzheimer's disease and 41 had mild cognitive impairment, while the others had normal cognitive function. All of the participants did a sleep study, as well as scans for biomarkers that indicated Alzheimer's. The researchers discovered that people who took longer to get to the REM stage of sleep were more likely to have biomarkers of Alzheimer's disease. Is there a relationship between sleep and Alzheimer's? The relationship between sleep and Alzheimer's disease is still being explored. The Alzheimer's Society notes that people living with dementia tend to have sleep issues, but the evidence is currently unclear on whether poor sleep is a risk factor for the disease. However, some research suggests that poor sleep could raise your risk of Alzheimer's. A study published in November found that 35 percent of people who were considered poor sleepers (and felt excessively tired during the day as a result) went on to develop motoric cognitive risk syndrome (MCR), which is considered a precursor to dementia. 'Poor sleep quality has been linked to Alzheimer's disease,' says W. Christopher Winter, MD, a neurologist and sleep medicine physician with Charlottesville Neurology and Sleep Medicine and host of the podcast. 'Conversely, individuals who sleep well, and get consistent amounts of sleep on a consistent schedule, seem to reduce their risk of cognitive impairment.' Can a lack of REM sleep increase my risk of Alzheimer's? It's hard to say for sure at this point. While the researchers concluded that more studies are needed, they also said a slower movement to REM sleep could serve as a 'potential marker' for Alzheimer's disease. Given that good sleep is linked to good overall health, it can't hurt to try to improve your sleep. How can I get more REM sleep? Most people go through four to six sleep cycles a night, and REM sleep is part of that. Unfortunately, you can't dictate the stages of sleep you enter and when. What you can do is try to focus on getting good sleep, period. Winter offers up these tips to help support good sleep: Have a set bedtime and wake time, and do your best to stick to it. Limit alcohol and caffeine, especially avoiding caffeine later in the day. Try to be physically active, and aim to work out in the mornings to support your body's natural sleep/wake cycle. Create a good, consistent bedtime routine that helps you wind down for the evening. Be wary of sleep aids. 'Ironically, some sleep aids affect REM sleep,' Winter says. How can I reduce my risk of Alzheimer's? Researchers don't know exactly what causes Alzheimer's disease and dementia, making it tough to know for sure how to prevent it. But the Centers for Disease Control and Prevention (CDC) recommends doing these things to help lower your risk: Be physically active Try to prevent or manage diabetes Manage your blood pressure Try to prevent or correct hearing loss Try to limit or avoid drinking alcohol Try to limit or avoid smoking If you're struggling with sleep, Winter says it's important to consult with a healthcare professional sooner rather than later. They should be able to do a sleep study—which can give you more information on what's behind your sleep issues—and make personalized recommendations from there. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
